Epidemiological and immunological features of obesity and SARS-CoV-2.
COVID-19
SARS-CoV-2
epidemiology
immunity
obesity
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
11 Dec 2020
11 Dec 2020
Historique:
pubmed:
18
11
2020
medline:
18
11
2020
entrez:
17
11
2020
Statut:
epublish
Résumé
Obesity is a key correlate of severe SARS-CoV-2 outcomes while the role of obesity on risk of SARS-CoV-2 infection, symptom phenotype, and immune response are poorly defined. We examined data from a prospective SARS-CoV-2 cohort study to address these questions. Serostatus, body mass index, demographics, comorbidities, and prior COVID-19 compatible symptoms were assessed at baseline and serostatus and symptoms monthly thereafter. SARS-CoV-2 immunoassays included an IgG ELISA targeting the spike RBD, multiarray Luminex targeting 20 viral antigens, pseudovirus neutralization, and T cell ELISPOT assays. Our results from a large prospective SARS-CoV-2 cohort study indicate symptom phenotype is strongly influenced by obesity among younger but not older age groups; we did not identify evidence to suggest obese individuals are at higher risk of SARS-CoV-2 infection; and, remarkably homogenous immune activity across BMI categories suggests natural- and vaccine-induced protection may be similar across these groups.
Identifiants
pubmed: 33200139
doi: 10.1101/2020.11.11.20229724
pmc: PMC7668749
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : Wellcome Trust
ID : 206250/Z/17/Z
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : U19 AI135995
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Lancet Infect Dis. 2006 Jul;6(7):438-46
pubmed: 16790384
MMWR Morb Mortal Wkly Rep. 2009 Jul 17;58(27):749-52
pubmed: 19609249
Clin Microbiol Rev. 2019 Mar 13;32(2):
pubmed: 30867162
Int J Obes (Lond). 2012 Aug;36(8):1072-7
pubmed: 22024641
Metabol Open. 2020 Dec;8:100057
pubmed: 32924000
Vaccine. 2015 Aug 26;33(36):4422-9
pubmed: 26163925
Immunity. 2020 Sep 15;53(3):524-532.e4
pubmed: 32783920
Front Immunol. 2020 Jun 16;11:1441
pubmed: 32612615
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
J Immunol. 2013 Sep 1;191(5):2474-85
pubmed: 23904168
Clin Infect Dis. 2021 Oct 5;73(7):e1855-e1862
pubmed: 32841322
J Immunol. 2010 Mar 15;184(6):3127-33
pubmed: 20173021
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Endocrinol Diabetes Metab. 2020 Aug 14;4(1):e00176
pubmed: 32904932
PLoS Negl Trop Dis. 2015 Jul 16;9(7):e0003846
pubmed: 26181387
J Immunol Methods. 2020 Sep - Oct;484-485:112832
pubmed: 32780998
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21011-21013
pubmed: 32788355
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
BMC Public Health. 2014 Feb 11;14:147
pubmed: 24517715
Obesity (Silver Spring). 2020 Oct;28(10):1815-1825
pubmed: 32602202
Int J Obes (Lond). 2017 Sep;41(9):1324-1330
pubmed: 28584297
Front Immunol. 2020 Jul 21;11:1714
pubmed: 32793244
Clin Infect Dis. 2011 Sep;53(5):413-21
pubmed: 21844024
Lancet. 2020 May 16;395(10236):1544-1545
pubmed: 32380044
J Appl Lab Med. 2021 Nov 1;6(6):1561-1570
pubmed: 34196711
Ann Intern Med. 2020 Nov 17;173(10):773-781
pubmed: 32783686